WuXi Biologics (Cayman) Statistics Share Statistics WuXi Biologics (Cayman) has 4.07B
shares outstanding. The number of shares has increased by -2.06%
in one year.
Shares Outstanding 4.07B Shares Change (YoY) -2.06% Shares Change (QoQ) -0.93% Owned by Institutions (%) n/a Shares Floating 3.54B Failed to Deliver (FTD) Shares n/a FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 5.13M, so 0% of the outstanding
shares have been sold short.
Short Interest 5.13M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 999.99
Valuation Ratios The PE ratio is 19.26 and the forward
PE ratio is 3.32.
WuXi Biologics (Cayman)'s PEG ratio is
-0.22.
PE Ratio 19.26 Forward PE 3.32 PS Ratio 3.46 Forward PS 0.6 PB Ratio 1.55 P/FCF Ratio 50.21 PEG Ratio -0.22
Financial Ratio History Enterprise Valuation WuXi Biologics (Cayman) has an Enterprise Value (EV) of 61.31B.
EV / Sales 3.28 EV / EBITDA 9.54 EV / EBIT 11.75 EV / FCF 47.62
Financial Position The company has a current ratio of 2.73,
with a Debt / Equity ratio of 0.12.
Current Ratio 2.73 Quick Ratio 2.56 Debt / Equity 0.12 Debt / EBITDA 0.77 Debt / FCF 3.84 Interest Coverage 31.56
Financial Efficiency Return on Equity is 8.03% and Return on Invested Capital is 7.96%.
Return on Equity 8.03% Return on Assets 5.89% Return on Invested Capital 7.96% Revenue Per Employee $1.49M Profits Per Employee $266.89K Employee Count 12,575 Asset Turnover 0.33 Inventory Turnover 7.25
Taxes Income Tax 889.03M Effective Tax Rate 18.39%
Stock Price Statistics The stock price has increased by 160.14% in the
last 52 weeks. The beta is 0.5, so WuXi Biologics (Cayman)'s
price volatility has been higher than the market average.
Beta 0.5 52-Week Price Change 160.14% 50-Day Moving Average 3.4 200-Day Moving Average 2.8 Relative Strength Index (RSI) 65.99 Average Volume (20 Days) 1,145
Income Statement In the last 12 months, WuXi Biologics (Cayman) had revenue of 18.68B
and earned 3.36B
in profits. Earnings per share was 0.11.
Revenue 18.68B Gross Profit 7.65B Operating Income 4.97B Net Income 3.36B EBITDA 6.43B EBIT 4.99B Earnings Per Share (EPS) 0.11
Full Income Statement Balance Sheet The company has 8.28B in cash and 4.94B in
debt, giving a net cash position of 3.34B.
Cash & Cash Equivalents 8.28B Total Debt 4.94B Net Cash 3.34B Retained Earnings 16.36B Total Assets 56.98B Working Capital 14.95B
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 5.22B
and capital expenditures -3.93B, giving a free cash flow of 1.29B.
Operating Cash Flow 5.22B Capital Expenditures -3.93B Free Cash Flow 1.29B FCF Per Share 0.32
Full Cash Flow Statement Margins Gross margin is 40.97%, with operating and profit margins of 26.63% and 17.97%.
Gross Margin 40.97% Operating Margin 26.63% Pretax Margin 25.89% Profit Margin 17.97% EBITDA Margin 34.43% EBIT Margin 26.63% FCF Margin 6.89%
Dividends & Yields WXIBF does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 5.19% FCF Yield 1.99%
Dividend Details Analyst Forecast Currently there are no analyst rating for WXIBF.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value $0.55 Lynch Upside -85.71% Graham Number 13.77 Graham Upside 257.66%
Stock Splits The last stock split was on Dec 10, 2020. It was a
forward
split with a ratio of 3:1.
Last Split Date Dec 10, 2020 Split Type forward Split Ratio 3:1
Scores Altman Z-Score 2.69 Piotroski F-Score 9
